查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1931185

全球血脂检测套组市场（按产品类型、检测类型、技术、最终用户和分销管道划分）预测（2026-2032年）

Blood Lipid Test Kits Market by Product Type, Test Type, Technology, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，血脂检测套组市场价值将达到 6.7146 亿美元，到 2026 年将成长至 7.065 亿美元，到 2032 年将达到 10.2708 亿美元，复合年增长率为 6.25%。

关键市场统计数据
基准年 2025 6.7146亿美元
预计年份：2026年 7.065亿美元
预测年份 2032 1,027,080,000 美元
复合年增长率 (%) 6.25%

关于不断变化的临床、技术和操作方面的考虑因素的背景介绍，这些因素正在重新定义临床路径中的脂质检测。

血脂检测领域横跨临床诊疗、消费者健康和科研三大领域，既需要严谨的技术，也需要切实可行的应用模式。检测化学、小型化分析仪和数位化监测技术的进步，拓展了血脂指标的检测范围和方式，使临床医生和患者能够从间歇性检测转向更连续、更具情境性的评估。同时，监管、报销考量和工作流程整合要求等因素，仍在影响哪些技术能够广泛应用。

脂质检测领域的变革性诊断融合了照护现场技术、试剂革新、数位整合和供应链敏捷性。

诊断领域的最新变革正在重塑脂质检测的开发、检验和应用方式。照护现场分析仪的创新将检查室级的功能整合到紧凑的桌上型和携带式设备中，使临床上可接受的脂质检测能够在患者附近进行。同时，试剂研发也更加重视长期保质期、简化工作流程以及与自动化检查室的兼容性，从而降低了传统集中式和分散式检查模式之间的壁垒。

评估美国关税调整对诊断产品采购、製造和分销动态的多方面营运和供应链影响

美国政策变化和关税制度调整正对整个诊断价值链产生实际影响，波及采购决策、供应商关係和库存管理实务。关税变化影响进口仪器零件、特殊试剂和耗材，迫使采购部门重新评估其供应商多元化策略和总到岸成本。为此，一些製造商和经销商正在重新评估其生产基地、供应商合约和库存缓衝，以降低进口成本波动带来的风险。

将推动市场采用的因素与产品类型、检测方式、终端用户需求、试剂化学性质、分销管道和脂质分析物优先级联繫起来的可操作的细分洞察

精细化的细分框架能够提供切实可行的洞察，帮助我们了解不同产品、测试形式、最终用户、技术和分销模式的采用路径和效能预期。就产品类型而言，设备包括用于中心检查室的桌上型分析仪和照护现场检测的即时分析仪；而试剂和耗材则分为试剂盒和试纸条，必须符合分析仪的兼容性和工作流程要求。这种差异化决定了产品开发的重点：设备製造商专注于通量、准确性和符合人体工学的设计，而试剂供应商则强调稳定性、批间一致性和简化的通讯协定。

各区域（美洲、欧洲、中东和非洲、亚太地区）的诊断应用模式和商业化需求将指南我们的区域市场策略。

区域趋势将对应用模式和商业化策略产生重要影响。在美洲，对整合式医疗路径的重视、强大的临床实验室网路以及消费者对居家监测日益增长的需求，都推动了对桌上型分析仪和先进的照护现场的兴趣。私人和公共支付方的结构会影响采购行为，而监管路径和报销政策则决定了新型设备进入临床实践的速度。

透过平台多功能性、供应弹性和数位化整合，制定竞争和合作策略，使製造商、试剂供应商和通路合作伙伴脱颖而出。

在血脂检测领域，竞争优势取决于技术差异化、试剂生态系统、服务和支援能力以及策略联盟的综合作用。主要企业正致力于提昇平台的多功能性，使仪器能够执行多种检测，从而提高其在临床工作流程中的效用。同时，那些能够确保试剂供应链稳定并提供完善品管系统的製造商，正在为高通量检查室和分散式医疗机构创造可持续的价值提案。

製造商和相关人员可采取的切实可行的策略重点，以加强其平台、保障其供应链、加速数位整合并改善客户体验。

为了将市场动态转化为永续优势，产业领导者应优先考虑以下关键倡议：首先，透过投资平台模组化，简化终端用户的采购流程，该平台应同时支援高通量桌上型分析仪和携带式照护现场设备，并确保不同产品系列之间的试剂相容性。这将降低检查室的准入门槛，并支援在医疗机构中大规模部署。

本研究采用全面且经过验证的检验调查方法，结合关键相关人员访谈、二手文献回顾和供应链压力测试，以得出可靠的研究结果。

本摘要的研究途径融合了定性和定量资料收集，并采用严格的检验程序，以确保研究结果具有可操作性和实证性。主要资料来源包括对临床实验室主任、采购人员、临床终端使用者和诊断行业高管进行结构化访谈，以收集有关性能、工作流程和采购方面的实际考虑。此外，还对供应商进行了访谈，以了解生产限制、试剂稳定性改进和分销策略。

摘要强调了以下共识：诊断品质、可近性、互通性和供应链韧性是未来应用的关键驱动因素。

本次调查的综合结果表明，血脂检测正经历着一场由技术创新、数位整合和医疗模式变革所驱动的变革。儘管诊断的准确性和可靠性仍然至关重要，但施行地点、检测结果如何融入医疗流程以及如何维持稳定的供应链供应，这些因素正日益成为定义其价值的关键所在。随着相关人员不断调整，集中式检查室的准确性与分散式检测的可及性之间的平衡将决定临床实践中最终采用的解决方案。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依产品类型分類的血脂检测套组市场

  • 装置
  • 试剂和耗材
    • 成套工具
    • 条

第九章 依检测类型分類的血脂检测套组市场

  • 自动分析仪
  • 即时检测

第十章 依技术分類的血脂检测套组市场

  • 干化学
  • 液体试剂

第十一章 以最终用户分類的血脂检测套组市场

  • 临床检查室
  • 居家医疗环境
  • 医院和诊所
  • 研究所

第十二章 血脂检测套组市场（依通路划分）

  • 离线
  • 在线的

第十三章 血脂检测套组市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 血脂检测套组市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国血脂检测套组市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国血脂检测套组市场

第十七章 中国血脂检测套组市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Alfresa Holdings Corporation
  • ARKRAY, Inc.
  • Asahi Kasei Corporation
  • Beckman Coulter, Inc.
  • bioMerieux SA
  • Daiichi Sankyo Company, Limited
  • Denka Seiken Co., Ltd.
  • Eiken Chemical Co., Ltd.
  • F. Hoffmann-La Roche AG
  • Fujifilm Wako Shibayagi Corporation
  • Horiba, Ltd.
  • Kyowa Medex Co., Ltd.
  • Mitsubishi Chemical Medience Corporation
  • Nitto Boseki Co., Ltd.
  • Ortho Clinical Diagnostics
  • Randox Laboratories Ltd.
  • Sekisui Medical Co., Ltd.
  • Shino-Test Corporation
  • Siemens Healthineers AG
  • SRL, Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Toyobo Co., Ltd.
  • Wako Pure Chemical Industries, Ltd.
Product Code: MRR-7B550E008DA5

The Blood Lipid Test Kits Market was valued at USD 671.46 million in 2025 and is projected to grow to USD 706.50 million in 2026, with a CAGR of 6.25%, reaching USD 1,027.08 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 671.46 million
Estimated Year [2026] USD 706.50 million
Forecast Year [2032] USD 1,027.08 million
CAGR (%) 6.25%

Contextual introduction to the evolving clinical, technological, and operational considerations that are redefining blood lipid testing across care pathways

The landscape of blood lipid testing intersects clinical care, consumer health, and research in ways that demand both technical rigor and pragmatic delivery models. Advances in assay chemistry, miniaturized analyzers, and digital monitoring have expanded where and how lipid metrics are captured, enabling clinicians and patients to move beyond episodic testing toward more continuous and contextualized assessment. At the same time, regulatory scrutiny, reimbursement considerations, and workflow integration requirements continue to shape which technologies achieve widespread adoption.

This executive summary synthesizes the critical vectors influencing diagnostic performance, procurement decisions, and clinical utility. It foregrounds how device form factors, reagent stability, and interoperability with electronic health records converge with care delivery models to influence uptake. The narrative emphasizes practical implications for manufacturers, laboratory directors, procurement officers, and clinical leaders, highlighting operational levers that can accelerate adoption while maintaining analytical quality.

Throughout this document, the focus remains on translating technological and policy developments into decision-useful insights. The objective is to inform strategy and operational planning for stakeholders seeking to align product roadmaps, distribution strategies, and clinical partnerships with evolving diagnostic requirements and user expectations.

Transformative forces in diagnostics driving convergence of point-of-care technology, reagent evolution, digital integration, and supply chain agility in lipid testing

Recent shifts within diagnostics are reframing how lipid tests are developed, validated, and deployed across multiple settings. Innovations in point-of-care analyzers have compressed laboratory capabilities into compact benchtop and handheld devices, allowing clinically acceptable lipid measurements to be obtained closer to patients. Concurrently, reagent development has emphasized longer shelf life, simplified workflows, and compatibility with automated platforms, reducing the friction that historically separated central laboratories from decentralized testing models.

Digital capabilities have further accelerated transformation by enabling remote result delivery, longitudinal trend visualization, and integration with care management platforms. These capabilities facilitate clinician oversight while empowering patients to engage with their lipid profiles more proactively. In addition, the convergence of wearable sensors and connected handheld devices supports earlier detection of metabolic risk and better adherence monitoring, prompting new clinical pathways that emphasize prevention and chronic disease management.

Supply chain optimization and manufacturing modularity are also reshaping vendor strategies. Producers are prioritizing platform flexibility and reagent standardization to serve both high-throughput laboratories and point-of-care environments. As a result, stakeholders must balance innovation with regulatory, quality, and interoperability demands to successfully navigate the transition toward more distributed, digitally enabled lipid testing ecosystems.

Evaluating the multifaceted operational and supply chain ramifications of United States tariff adjustments on diagnostic procurement, manufacturing, and distribution dynamics

Policy changes and adjustments to tariff regimes in the United States introduce tangible effects along the diagnostic value chain, influencing procurement decisions, supplier relationships, and inventory management practices. Tariff changes affect imported instrumentation components, specialized reagents, and consumables, prompting purchasing teams to reassess supplier diversification strategies and total landed costs. In response, some manufacturers and distributors are reevaluating production locations, supplier contracts, and inventory buffers to mitigate exposure to import cost volatility.

The immediate operational implications include longer lead times for certain imported components and selective reallocation of sourcing toward domestic or tariff-exempt suppliers where feasible. These adjustments create both short-term logistical complexity and longer-term strategic opportunities for local manufacturing partnerships and regional supply hubs. Procurement functions are increasingly incorporating scenario planning and supplier scorecards that capture tariff risk, supplier resilience, and contingency capacity.

Clinicians and laboratory managers may encounter pricing adjustments for specific consumables or bundled systems, which can influence ordering cadence and stocking policies. To preserve continuity of care and testing throughput, laboratories are prioritizing forecasting discipline and supplier engagement to ensure uninterrupted access to critical reagents and strips. Overall, tariff-driven shifts are amplifying the importance of supply chain transparency, flexible sourcing, and collaborative risk-sharing arrangements across the diagnostic ecosystem.

Actionable segmentation insights that link product categories, test modalities, end-user needs, reagent chemistries, distribution channels, and lipid analyte priorities to adoption drivers

A nuanced segmentation framework yields practical insights into adoption pathways and performance expectations across products, test formats, end users, technologies, and distribution models. When product type is considered, instruments encompass benchtop analyzers suited for central laboratories and point-of-care analyzers designed for near-patient testing, while reagents and consumables are differentiated into kits and strips that must align with analyzer compatibility and workflow requirements. This differentiation informs product development priorities, with instrument manufacturers focusing on throughput, accuracy, and ergonomics and reagent suppliers emphasizing stability, lot-to-lot consistency, and simplified protocols.

Examining test type reveals a bifurcation between automated analyzers that deliver high-throughput, standardized results and point-of-care testing modalities that include handheld devices and emerging wearable sensors. The trade-offs between convenience and analytical performance shape clinical adoption, with automated platforms favored where diagnostic precision and volume are paramount and point-of-care tools prioritized in settings that value rapid decision-making and decentralized access. End user dynamics further influence product requirements: clinical laboratories demand integration, calibration protocols, and serviceability; home care settings emphasize ease of use and remote connectivity; hospitals and clinics require interoperability with health IT systems; and research institutes focus on analytical flexibility and data granularity.

Technology choices between dry chemistry and liquid reagents have implications for storage, shelf life, and calibration regimes, affecting both operational workflows and user training. Distribution channels-direct sales, distributors, and online retail-each present unique commercialization pathways that influence pricing strategy, after-sales service expectations, and regulatory compliance responsibilities. Finally, lipid type segmentation across high-density lipoprotein, low-density lipoprotein, total cholesterol, and triglycerides has clinical significance that dictates assay design, validation needs, and reporting formats to meet the diagnostic and therapeutic decision points used by clinicians.

Regional diagnostic adoption patterns and commercialization imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that inform tailored market approaches

Regional dynamics shape adoption models and commercialization strategies in meaningful ways. In the Americas, emphasis on integrated care pathways, strong clinical laboratory networks, and increasing consumer demand for home monitoring have catalyzed interest in both benchtop analyzers and advanced point-of-care solutions. Private and public payor structures influence procurement behaviors, while regulatory pathways and reimbursement policy determine the speed at which new device classes can scale within clinical practice.

In Europe, the Middle East & Africa, clinical and regulatory diversity creates a landscape where centralized laboratory infrastructure remains pivotal in many markets, but pockets of rapid point-of-care adoption are emerging in community health settings and private clinics. Supply chain constraints and local manufacturing priorities in some jurisdictions necessitate flexible commercial models and tailored service offerings. Interoperability with regional health information systems and alignment with public health screening initiatives are critical levers for broader adoption.

Asia-Pacific exhibits heterogenous adoption patterns driven by rapid urbanization, growing investment in primary care, and significant interest in consumer-facing diagnostics. High-density population centers create attractive volumes for scalable point-of-care deployments, while certain markets prioritize local manufacturing and cost control. Across regions, distribution strategies must be adapted to local procurement practices, regulatory expectations, and clinician preferences to ensure successful market entry and sustained uptake.

Competitive and partnership strategies that differentiate manufacturers, reagent suppliers, and channel partners through platform versatility, supply resilience, and digital integration

Competitive positioning in the blood lipid testing space is defined by a mix of technological differentiation, reagent ecosystems, service and support capabilities, and strategic partnerships. Leading companies are investing in platform versatility that allows instruments to process multiple analytes, thereby increasing utility across clinical workflows. At the same time, manufacturers that secure stable reagent supply chains and provide robust quality management systems create durable value propositions for high-volume laboratories and decentralized care sites.

Strategic partnerships between device manufacturers, reagent producers, and distribution networks are increasingly common, enabling bundled solutions that simplify procurement and technical support. Companies that offer digital integration tools-such as secure result transmission, data analytics, and EHR interoperability-gain an edge by reducing clinician burden and improving longitudinal patient management. Service models that combine preventive maintenance, rapid parts replacement, and remote troubleshooting reduce downtime and enhance customer loyalty.

New entrants and niche innovators are focusing on wearable sensors and consumer-oriented products, creating complementary value alongside established clinical platforms. These entrants often pursue collaborations with research institutions and healthcare systems to validate clinical utility and build clinician confidence. In aggregate, successful companies will be those that balance innovation with regulatory rigor, dependable supply chains, and after-sales excellence to meet diverse end-user requirements.

Practical strategic priorities for manufacturers and stakeholders to strengthen platforms, secure supply chains, accelerate digital integration, and enhance customer outcomes

Industry leaders should prioritize a set of targeted actions to convert market dynamics into sustainable advantages. First, invest in platform modularity that supports both high-throughput benchtop analyzers and portable point-of-care devices, while ensuring reagent compatibility across product families to simplify procurement for end users. This reduces friction for laboratory adoption and enables scalable rollouts across care settings.

Second, strengthen supply chain resilience by diversifying suppliers, establishing regional inventory hubs, and negotiating contingency agreements that mitigate the impact of tariff or logistics disruptions. Transparent supplier scorecards and scenario planning should be embedded in procurement and product launch processes. Third, accelerate digital integration by developing secure interoperability features that connect test results with electronic health records and patient management platforms, thereby increasing clinical workflow efficiency and enabling value-based care models.

Fourth, enhance customer support through outcome-focused service offerings that combine preventive maintenance, rapid response, and user training programs tailored to clinical and home settings. Fifth, pursue strategic collaborations with clinical networks, research institutions, and payors to generate real-world evidence that underscores clinical utility and supports reimbursement discussions. By aligning product design, commercial models, and operational resilience with user needs, industry leaders can accelerate adoption and create defensible differentiation.

Comprehensive and validated research methodology leveraging primary stakeholder interviews, secondary literature synthesis, and supply chain stress-testing for robust insights

The research approach underpinning this summary integrated qualitative and quantitative data collection with robust validation steps to ensure findings are actionable and evidence-based. Primary inputs included structured interviews with clinical laboratory directors, procurement leads, clinician end users, and diagnostic industry executives to capture practical considerations around performance, workflow, and procurement. These conversations were complemented by targeted supplier interviews to understand manufacturing constraints, reagent stability improvements, and distribution strategies.

Secondary sources comprised peer-reviewed literature on assay performance and clinical utility, regulatory guidance documents, and public policy analyses that inform reimbursement and procurement frameworks. Supply chain assessments evaluated component sourcing, logistics dependencies, and potential tariff exposures to identify operational risk points. Throughout the analysis, triangulation was used to reconcile differing perspectives and validate emergent themes, with particular attention to analytical accuracy, regulatory compliance, and real-world usability.

Where applicable, findings were stress-tested through scenario analysis focused on sourcing disruptions, reimbursement shifts, and rapid technology adoption. This layered methodology ensures that recommendations are grounded in practitioner experience and validated against documented evidence and supply chain realities.

Concluding synthesis highlighting the alignment of diagnostic quality, access, interoperability, and supply chain resilience as decisive factors for future adoption

Collectively, the insights synthesized here underscore that blood lipid testing is undergoing a period of purposeful evolution driven by technology, digital integration, and shifting care models. Diagnostic accuracy and reliability remain non-negotiable, yet value is increasingly defined by where and how tests are performed, how results are integrated into care pathways, and how supply chains sustain availability. As stakeholders adapt, a balance between centralized laboratory precision and decentralized accessibility will determine which solutions achieve clinical traction.

Organizations that invest in platform interoperability, reagent stability, and resilient sourcing will be better positioned to respond to clinician needs and procurement dynamics. Simultaneously, clear evidence of clinical utility and cost-effectiveness will facilitate conversations with payors and procurement authorities, supporting broader adoption. Leadership in this space will require not only technological excellence but also disciplined execution across commercialization, regulatory engagement, and post-market support.

Ultimately, the trajectory of blood lipid testing will favor solutions that make high-quality diagnostics more accessible across care settings while preserving analytical integrity. Stakeholders that align product design, service models, and strategic partnerships to those priorities stand to deliver measurable improvements in preventive care and chronic disease management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Lipid Test Kits Market, by Product Type

  • 8.1. Instruments
  • 8.2. Reagents & Consumables
    • 8.2.1. Kits
    • 8.2.2. Strips

9. Blood Lipid Test Kits Market, by Test Type

  • 9.1. Automated Analyzers
  • 9.2. Point Of Care Testing

10. Blood Lipid Test Kits Market, by Technology

  • 10.1. Dry Chemistry
  • 10.2. Liquid Reagents

11. Blood Lipid Test Kits Market, by End User

  • 11.1. Clinical Laboratories
  • 11.2. Home Care Settings
  • 11.3. Hospitals And Clinics
  • 11.4. Research Institutes

12. Blood Lipid Test Kits Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Blood Lipid Test Kits Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Blood Lipid Test Kits Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Blood Lipid Test Kits Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Blood Lipid Test Kits Market

17. China Blood Lipid Test Kits Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Alfresa Holdings Corporation
  • 18.7. ARKRAY, Inc.
  • 18.8. Asahi Kasei Corporation
  • 18.9. Beckman Coulter, Inc.
  • 18.10. bioMerieux SA
  • 18.11. Daiichi Sankyo Company, Limited
  • 18.12. Denka Seiken Co., Ltd.
  • 18.13. Eiken Chemical Co., Ltd.
  • 18.14. F. Hoffmann-La Roche AG
  • 18.15. Fujifilm Wako Shibayagi Corporation
  • 18.16. Horiba, Ltd.
  • 18.17. Kyowa Medex Co., Ltd.
  • 18.18. Mitsubishi Chemical Medience Corporation
  • 18.19. Nitto Boseki Co., Ltd.
  • 18.20. Ortho Clinical Diagnostics
  • 18.21. Randox Laboratories Ltd.
  • 18.22. Sekisui Medical Co., Ltd.
  • 18.23. Shino-Test Corporation
  • 18.24. Siemens Healthineers AG
  • 18.25. SRL, Inc.
  • 18.26. Sysmex Corporation
  • 18.27. Thermo Fisher Scientific Inc.
  • 18.28. Toyobo Co., Ltd.
  • 18.29. Wako Pure Chemical Industries, Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD LIPID TEST KITS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLOOD LIPID TEST KITS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BLOOD LIPID TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BLOOD LIPID TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY STRIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY STRIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY STRIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY AUTOMATED ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY AUTOMATED ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY AUTOMATED ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY DRY CHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY DRY CHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY DRY CHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY LIQUID REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY LIQUID REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY LIQUID REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS BLOOD LIPID TEST KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. GCC BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GCC BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 118. GCC BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. GCC BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. GCC BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. G7 BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 139. G7 BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. G7 BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. G7 BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. NATO BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 146. NATO BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NATO BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. NATO BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. NATO BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BLOOD LIPID TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES BLOOD LIPID TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA BLOOD LIPID TEST KITS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA BLOOD LIPID TEST KITS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA BLOOD LIPID TEST KITS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA BLOOD LIPID TEST KITS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA BLOOD LIPID TEST KITS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA BLOOD LIPID TEST KITS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA BLOOD LIPID TEST KITS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)